NASDAQ:AMGN - Amgen Stock Price, Price Target & More

$171.56 -1.37 (-0.79 %)
(As of 04/22/2018 12:03 PM ET)
Previous Close$171.56
Today's Range$170.57 - $173.47
52-Week Range$152.16 - $201.23
Volume2.96 million shs
Average Volume3.27 million shs
Market Capitalization$114.65 billion
P/E Ratio13.64
Dividend Yield3.08%
Beta1.36

About Amgen (NASDAQ:AMGN)

Amgen logoAmgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It offers products for the treatment of oncology/hematology, cardiovascular, inflammation, bone health, nephrology, and neuroscience. The company's products include Evenity to treat osteoporosis in postmenopausal women; Prolia to treat postmenopausal women with osteoporosis; Xgeva for skeletal-related events prevention; Repatha to treat coronary diseases; Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Parsabiv to treat secondary hyperparathyroidism (sHPT); and Aimovig for the prevention of migraine. Its products also comprise Blincyto to treat patients with Philadelphia chromosome-negative relapsed or refractory B-cell precursor acute lymphoblastic leukemia; Kyprolis, a proteasome inhibitor for the treatment of multiple myeloma and small-cell lung cancer; Nplate, a thrombopoietic compound. The company's marketed products include Neulasta, a pegylated protein to treat cancer patients; Aranesp to treat anemia; Sensipar/Mimpara products to treat sHPT in chronic kidney disease; EPOGEN to treat a lower-than-normal number of red blood cells; NEUPOGEN, a recombinant human granulocyte colony-stimulating factor; and IMLYGIC to treat various cancer cells. It serves pharmaceutical wholesale distributors; and physicians or their clinics, dialysis centers, hospitals, and pharmacies, as well as consumers. The company has collaborative agreements with Pfizer Inc.; UCB; Bayer HealthCare Pharmaceuticals Inc. Amgen Inc. was founded in 1980 and is headquartered in Thousand Oaks, California.

Receive AMGN News and Ratings via Email

Sign-up to receive the latest news and ratings for AMGN and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryBiotechnology
SectorMedical
SymbolNASDAQ:AMGN
CUSIP03116210
Phone805-447-1000

Debt

Debt-to-Equity Ratio1.35%
Current Ratio5.49%
Quick Ratio5.17%

Price-To-Earnings

Trailing P/E Ratio13.64
Forward P/E Ratio12.92
P/E Growth2.1

Sales & Book Value

Annual Sales$22.85 billion
Price / Sales5.02
Cash Flow$15.4281 per share
Price / Cash11.12
Book Value$34.77 per share
Price / Book4.93

Profitability

EPS (Most Recent Fiscal Year)$12.58
Net Income$1.98 billion
Net Margins8.66%
Return on Equity30.87%
Return on Assets11.64%

Miscellaneous

Employees20,800
Outstanding Shares668,270,000

How to Become a New Pot Stock Millionaire

Amgen (NASDAQ:AMGN) Frequently Asked Questions

What is Amgen's stock symbol?

Amgen trades on the NASDAQ under the ticker symbol "AMGN."

How often does Amgen pay dividends? What is the dividend yield for Amgen?

Amgen declared a quarterly dividend on Wednesday, March 7th. Stockholders of record on Thursday, May 17th will be given a dividend of $1.32 per share on Friday, June 8th. This represents a $5.28 annualized dividend and a dividend yield of 3.08%. The ex-dividend date is Wednesday, May 16th. View Amgen's Dividend History.

How will Amgen's stock buyback program work?

Amgen declared that its Board of Directors has approved a share buyback program on Friday, February 2nd 2018, which allows the company to repurchase $10,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization allows the company to buy shares of its stock through open market purchases. Shares repurchase programs are typically a sign that the company's management believes its shares are undervalued.

How were Amgen's earnings last quarter?

Amgen (NASDAQ:AMGN) announced its earnings results on Thursday, February, 1st. The medical research company reported $2.89 earnings per share for the quarter, missing analysts' consensus estimates of $3.03 by $0.14. The medical research company had revenue of $5.80 billion for the quarter, compared to analyst estimates of $5.84 billion. Amgen had a net margin of 8.66% and a return on equity of 30.87%. Amgen's revenue for the quarter was down 2.7% on a year-over-year basis. During the same period in the prior year, the company earned $2.89 earnings per share. View Amgen's Earnings History.

When is Amgen's next earnings date?

Amgen is scheduled to release their next quarterly earnings announcement on Thursday, April, 26th 2018. View Earnings Estimates for Amgen.

What guidance has Amgen issued on next quarter's earnings?

Amgen updated its FY18 earnings guidance on Thursday, February, 1st. The company provided earnings per share guidance of $12.60-13.70 for the period, compared to the Thomson Reuters consensus EPS estimate of $12.71. The company issued revenue guidance of $21.8-22.8 billion, compared to the consensus revenue estimate of $22.86 billion.

What price target have analysts set for AMGN?

23 Wall Street analysts have issued 12 month target prices for Amgen's stock. Their forecasts range from $161.00 to $220.00. On average, they anticipate Amgen's stock price to reach $190.8505 in the next year. View Analyst Ratings for Amgen.

What are Wall Street analysts saying about Amgen stock?

Here are some recent quotes from research analysts about Amgen stock:
  • 1. According to Zacks Investment Research, "Amgen’s newer drugs – Prolia, Xgeva, Kyprolis – are performing well.  Amgen is also progressing with its pipeline and expects approval and launch of migraine candidate, Aimovig this year. Amgen’s restructuring plan is making it leaner and more cost efficient. Lower taxes and share buybacks should provide some bottom-line support in 2018. Amgen’s shares have outperformed the industry this year so far. However, Amgen has some challenges in store, given slowdown in sales of mature drugs like Enbrel, Aranesp and Neulasta, which are facing an array of branded and generic competitors. Volume growth of new drugs may not be enough to offset the lost sales due to the decline in mature brands. Meanwhile, uptake of key new drug, Repatha has been slow due to payer restrictions. However, estimates have gone up ahead of the Q1 earnings release. Amgen has a positive record of earnings surprises in recent quarters." (4/17/2018)
  • 2. JPMorgan Chase analysts commented, "AMGN’s top-line continues to be uninspiring, but the bottom line will meaningfully benefit from a lower than expected tax rate (surprise, surprise) and a large, accelerated $10B share buyback. There are several moving pieces to consider heading into 2018 (which are apparent in management’s uncharacteristically wide guidance range), including timing/magnitude of legacy franchise erosion (e.g., Neulasta & Sensipar), trajectory of recent/upcoming launches (e.g., Kyprolis, Repatha, Aimovig), and the extent to which AMGN chooses to exercise its upsized share repurchase authorization (now ~$14B in total). While we continue to be keenly interested in potential for M&A (which AMGN continues to be constructive on) and the earlier stage pipeline, we maintain our Neutral rating pending evidence of sustainable near-/mid-term growth." (2/4/2018)
  • 3. Mizuho analysts commented, "We expect Q4 ’17 trends for both unit demand and net selling price to continue into 2018 – Expect Q1 ’18 sales to be ~ 20% of full year 2018 sales Neulasta US = 969 / 950 / 949 Neulasta Ex-US = 145 / 151 / 152 Neulasta WW = 1114/ 1103 / 1100 Neupogen US = 82 / 87 / 87 PLEASE REFER TO PAGE 5 OF THIS REPORT FOR IMPORTANT DISCLOSURE AND ANALYST CERTIFICATION INFORMATION. Mizuho Securities USA LLC does and seeks to do business with companies covered in its research reports. As a result, investors should be aware that the Firm may have a conflict of interest that could affect the objectivity of this report. Investors should consider this report as only a single factor in making their investment decision." (2/1/2018)
  • 4. Cann analysts commented, "Amgen yesterday announced that the New England Journal of Medicine (NEJM) published positive results from the six-month phase III STRIVE study evaluating Aimovig (erenumab) versus placebo for the prevention of episodic migraine (between four and 14 migraine days per month). The NEJM article reported that Aimovig delivered clinically meaningful and statistically significant differences from placebo for all primary and secondary endpoints in the study." (11/30/2017)
  • 5. Argus analysts commented, "We would consider a more constructive stance on AMGN on signs of stronger contributions from the company's new drug pipeline or from its biosimilars portfolio," the firm said."We note, however, that Amgen may not generate commercial revenue from biosimilars until 2019 due to regulatory and legal hurdles." (11/1/2017)

Are investors shorting Amgen?

Amgen saw a decrease in short interest in March. As of March 29th, there was short interest totalling 9,494,182 shares, a decrease of 51.8% from the March 15th total of 19,687,115 shares. Based on an average trading volume of 5,053,446 shares, the days-to-cover ratio is currently 1.9 days. Currently, 1.3% of the shares of the company are sold short.

Who are some of Amgen's key competitors?

Who are Amgen's key executives?

Amgen's management team includes the folowing people:
  • Mr. Robert A. Bradway, Chairman, CEO & Pres (Age 55)
  • Mr. David W. Meline, Exec. VP, CFO and Principal Financial & Accounting Officer (Age 61)
  • Mr. Jonathan P. Graham, Sr. VP, Gen. Counsel & Sec. (Age 57)
  • Dr. Sean E. Harper, Exec. VP of R&D (Age 55)
  • Mr. Anthony C. Hooper, Exec. VP of Global Commercial Operations (Age 63)

Has Amgen been receiving favorable news coverage?

News stories about AMGN stock have been trending somewhat positive on Sunday, Accern Sentiment Analysis reports. Accern ranks the sentiment of media coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Amgen earned a coverage optimism score of 0.07 on Accern's scale. They also gave news coverage about the medical research company an impact score of 46.19 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company's share price in the next several days.

How do I buy shares of Amgen?

Shares of AMGN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Amgen's stock price today?

One share of AMGN stock can currently be purchased for approximately $171.56.

How big of a company is Amgen?

Amgen has a market capitalization of $114.65 billion and generates $22.85 billion in revenue each year. The medical research company earns $1.98 billion in net income (profit) each year or $12.58 on an earnings per share basis. Amgen employs 20,800 workers across the globe.

How can I contact Amgen?

Amgen's mailing address is ONE AMGEN CENTER DRIVE, THOUSAND OAKS CA, 91320. The medical research company can be reached via phone at 805-447-1000 or via email at [email protected]


MarketBeat Community Rating for Amgen (AMGN)

Community Ranking:  3.0 out of 5 (star star star)
Outperform Votes:  1,044 (Vote Outperform)
Underperform Votes:  673 (Vote Underperform)
Total Votes:  1,717
MarketBeat's community ratings are surveys of what our community members think about Amgen and other stocks. Vote "Outperform" if you believe AMGN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe AMGN will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Amgen (NASDAQ:AMGN) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
23 Wall Street analysts have issued ratings and price targets for Amgen in the last 12 months. Their average twelve-month price target is $190.8505, suggesting that the stock has a possible upside of 11.24%. The high price target for AMGN is $220.00 and the low price target for AMGN is $161.00. There are currently 13 hold ratings and 10 buy ratings for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldHoldBuy
Consensus Rating Score: 2.432.432.432.52
Ratings Breakdown: 0 Sell Rating(s)
13 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
13 Hold Rating(s)
10 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
12 Hold Rating(s)
9 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
11 Hold Rating(s)
9 Buy Rating(s)
1 Strong Buy Rating(s)
Consensus Price Target: $190.8505$191.3505$190.00$190.4737
Price Target Upside: 11.24% upside10.31% upside5.64% upside4.11% upside

Amgen (NASDAQ:AMGN) Consensus Price Target History

Price Target History for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/5/2018BarclaysLower Price TargetEqual Weight -> Equal Weight$190.00 -> $180.00LowView Rating Details
2/12/2018MizuhoBoost Price TargetBuy -> Buy$192.00 -> $200.00LowView Rating Details
2/5/2018Atlantic SecuritiesDowngradeOverweight -> Neutral$187.01HighView Rating Details
2/4/2018JPMorgan ChaseReiterated RatingHold$191.00HighView Rating Details
2/2/2018Leerink SwannReiterated RatingMarket PerformHighView Rating Details
2/2/2018CowenReiterated RatingBuy$204.00LowView Rating Details
2/2/2018Credit Suisse GroupBoost Price TargetNeutral -> Neutral$191.00 -> $194.00LowView Rating Details
2/2/2018BMO Capital MarketsBoost Price TargetMarket Perform -> Market Perform$192.00 -> $202.00MediumView Rating Details
2/2/2018Morgan StanleyLower Price TargetOverweight -> Overweight$204.00 -> $196.00MediumView Rating Details
2/2/2018Piper JaffrayLower Price TargetOverweight -> Overweight$194.00 -> $190.00MediumView Rating Details
1/30/2018OppenheimerReiterated RatingBuy$205.00 -> $205.00LowView Rating Details
1/24/2018Royal Bank of CanadaReiterated RatingHold$189.00LowView Rating Details
1/23/2018ArgusUpgradeHold -> Buy$192.33 -> $220.00LowView Rating Details
12/18/2017CitigroupDowngradeNeutralLowView Rating Details
12/15/2017Goldman SachsDowngradeConviction-Buy -> BuyHighView Rating Details
11/30/2017CannReiterated RatingBuy$205.00HighView Rating Details
10/5/2017Bank of AmericaBoost Price TargetBuy$210.00N/AView Rating Details
9/25/2017Jefferies GroupReiterated RatingBuy$200.00LowView Rating Details
7/26/2017UBSSet Price TargetHold$175.00 -> $180.00HighView Rating Details
7/26/2017Deutsche BankReiterated RatingHold$172.00 -> $174.00LowView Rating Details
6/26/2017William BlairReiterated RatingMarket PerformLowView Rating Details
6/8/2017Sanford C. BernsteinSet Price TargetHold$164.00MediumView Rating Details
4/28/2017Robert W. BairdReiterated RatingNeutral$165.00LowView Rating Details
12/13/2016Chardan CapitalUpgradeSell -> NeutralN/AView Rating Details
8/26/2016GabelliInitiated CoverageHoldN/AView Rating Details
(Data available from 4/22/2016 forward)

Earnings

Amgen (NASDAQ:AMGN) Earnings History and Estimates Chart

Earnings by Quarter for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) Earnings Estimates

2018 EPS Consensus Estimate: $13.60
2019 EPS Consensus Estimate: $14.10
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20184$3.16$3.50$3.31
Q2 20183$3.24$3.55$3.44
Q3 20183$3.47$3.81$3.59
Q4 20184$3.13$3.39$3.25
Q1 20191$3.48$3.48$3.48
Q2 20191$3.56$3.56$3.56
Q3 20191$3.58$3.58$3.58
Q4 20191$3.48$3.48$3.48

Amgen (NASDAQ AMGN) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/26/2018$3.18N/AView Earnings Details
2/1/2018Q4 2017$3.03$2.89$5.8428 billion$5.8020 billionViewListenView Earnings Details
10/25/2017Q3 2017$3.11$3.27$5.7510 billion$5.7730 billionViewN/AView Earnings Details
7/25/2017Q2 2017$3.11$3.27$5.6656 billion$5.81 billionViewN/AView Earnings Details
4/26/2017Q1 2017$3.00$3.15$5.6047 billion$5.4640 billionViewN/AView Earnings Details
2/2/2017Q416$2.79$2.89$5.75 billion$5.9650 billionViewListenView Earnings Details
10/27/2016Q316$2.79$3.02$5.73 billion$5.8110 billionViewListenView Earnings Details
7/27/2016Q216$2.74$2.84$5.58 billion$5.6880 billionViewListenView Earnings Details
4/28/2016Q116$2.60$2.90$5.32 billion$5.53 billionViewListenView Earnings Details
1/28/2016Q415$2.29$2.61$5.53 billion$5.54 billionViewListenView Earnings Details
10/28/2015Q315$2.38$2.72$5.32 billion$5.7230 billionViewListenView Earnings Details
7/30/2015Q215$2.43$2.57$5.32 billion$5.37 billionViewListenView Earnings Details
4/21/2015Q115$2.07$2.48$4.91 billion$5.0330 billionViewListenView Earnings Details
1/27/2015Q414$2.05$2.16$5.20 billion$5.33 billionViewListenView Earnings Details
10/27/2014Q314$2.11$2.30$4.95 billion$5.03 billionViewListenView Earnings Details
7/29/2014Q214$2.07$2.37$4.90 billion$5.18 billionViewListenView Earnings Details
4/22/2014Q114$1.94$1.87$4.7569 billion$4.5210 billionViewListenView Earnings Details
1/28/2014Q413$1.69$1.82$4.81 billion$5.01 billionViewListenView Earnings Details
10/22/2013Q313$1.78$1.94$4.60 billion$4.75 billionViewListenView Earnings Details
7/30/2013Q2 2013$1.74$1.89$4.4909 billion$4.6790 billionViewListenView Earnings Details
4/23/2013Q1 2013$1.84$1.96$4.37 billion$4.2380 billionViewN/AView Earnings Details
1/23/2013Q4 2012$1.42$1.40$4.37 billion$4.4210 billionViewListenView Earnings Details
10/23/2012$1.47$1.67ViewN/AView Earnings Details
7/26/2012$1.54$1.83ViewN/AView Earnings Details
4/24/2012Q1 2012$1.43$1.59ViewN/AView Earnings Details
1/26/2012$1.22$1.21ViewN/AView Earnings Details
10/24/2011$1.29$1.40ViewN/AView Earnings Details
7/29/2011$1.29$1.37ViewN/AView Earnings Details
4/20/2011$1.29$1.34ViewN/AView Earnings Details
1/24/2011$1.11$1.17ViewN/AView Earnings Details
10/25/2010Q3 2010$1.26$1.36ViewN/AView Earnings Details
7/29/2010Q2 2010$1.28$1.34ViewN/AView Earnings Details
4/21/2010Q1 2010$1.23$1.28ViewN/AView Earnings Details
1/25/2010Q4 2009$1.11$1.05ViewN/AView Earnings Details
10/21/2009Q3 2009$1.25$1.49ViewN/AView Earnings Details
7/27/2009Q2 2009$1.15$1.27ViewN/AView Earnings Details
4/23/2009Q1 2009$1.13$1.08ViewN/AView Earnings Details
1/26/2009Q4 2008$1.04$1.04ViewN/AView Earnings Details
10/22/2008Q3 2008$1.06$1.21ViewN/AView Earnings Details
7/28/2008Q2 2008$0.98$1.13ViewN/AView Earnings Details
4/24/2008Q1 2008$1.02$1.10ViewN/AView Earnings Details
1/24/2008Q4 2007$0.92$0.97ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

Amgen (NASDAQ:AMGN) Dividend Information

Amgen pays an annual dividend of $5.28 per share, with a dividend yield of 3.08%. AMGN's next quarterly dividend payment will be made on Friday, June 8. The company has grown its dividend for the last 7 consecutive years and is increasing its dividend by an average of 23.50% each year. Amgen pays out 41.97% of its earnings out as a dividend.
Next Dividend:6/8/2018
Annual Dividend:$5.28
Dividend Yield:3.08%
Dividend Growth:23.50% (3 Year Average)
Payout Ratio:41.97% (Trailing 12 Months of Earnings)
39.76% (Based on This Year's Estimates)
38.12% (Based on Next Year's Estimates)
Track Record:7 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ:AMGN) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
3/7/2018quarterly$1.322.81554951207807%5/16/20185/17/20186/8/2018
12/12/2017quarterly$1.322.98%2/14/20182/15/20183/8/2018
10/24/2017quarterly$1.152.59%11/16/201711/17/201712/8/2017
7/28/2017quarterly$1.152.64%8/15/20178/17/20179/8/2017
3/7/2017quarterly$1.152.59%5/15/20175/17/20176/8/2017
12/20/2016quarterly$1.153.15%2/13/20172/15/20173/8/2017
10/14/2016quarterly$1.002.46%11/14/201611/16/201612/8/2016
7/22/2016quarterly$1.002.4%8/15/20168/17/20169/8/2016
3/2/2016quarterly$1.002.74%5/13/20165/17/20166/8/2016
12/15/2015quarterly$1.002.43%2/11/20162/16/20163/8/2016
10/14/2015quarterly$0.792.07%11/12/201511/16/201512/7/2015
7/28/2015quarterly$0.791.84%8/13/20158/17/20159/8/2015
3/4/2015quarterly$0.791.98%5/12/20155/14/20156/5/2015
12/17/2014quarterly$0.791.88%2/10/20152/12/20153/6/2015
10/17/2014quarterly$0.611.77%11/10/201411/13/201412/5/2014
7/25/2014quarterly$0.611.99%8/12/20148/14/20149/5/2014
3/5/2014quarterly$0.611.96%5/13/20145/15/20146/6/2014
12/13/2013quarterly$0.612.18%2/11/20142/13/20143/7/2014
10/16/2013quarterly$0.471.62%11/12/201311/14/201312/6/2013
7/26/2013quarterly$0.471.72%8/14/20138/16/20139/6/2013
3/6/2013quarterly$0.472.02%5/14/20135/16/20136/7/2013
12/13/2012quarterly$0.472.11%2/11/20132/13/20133/7/2013
(Data available from 1/1/2013 forward)

Insider Trades

Amgen (NASDAQ AMGN) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 0.19%
Institutional Ownership Percentage: 79.54%
Insider Trading History for Amgen (NASDAQ:AMGN)
Institutional Ownership by Quarter for Amgen (NASDAQ:AMGN)

Amgen (NASDAQ AMGN) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
4/12/2018Sean E. HarperEVPSell1,525$172.68$263,337.00View SEC Filing  
3/16/2018Sean E. HarperEVPSell1,525$189.75$289,368.75View SEC Filing  
2/14/2018Sean E. HarperEVPSell1,525$174.18$265,624.50View SEC Filing  
1/16/2018Sean E. HarperEVPSell1,525$185.62$283,070.50View SEC Filing  
12/12/2017Sean E HarperEVPSell1,525$176.83$269,665.7556,106View SEC Filing  
11/13/2017Sean E HarperEVPSell1,525$171.58$261,659.5057,631View SEC Filing  
11/8/2017Carbonnel Francois DeDirectorSell4,000$173.61$694,440.00View SEC Filing  
10/9/2017Sean E HarperEVPSell1,525$185.95$283,573.75View SEC Filing  
5/24/2017Cynthia M PattonSVPSell2,922$154.40$451,156.8024,214View SEC Filing  
8/2/2016Annette Louise SuchVPSell3,000$174.59$523,770.00View SEC Filing  
5/4/2016Madhavan BalachandranEVPSell30,000$154.12$4,623,600.0023,097View SEC Filing  
4/29/2016David BaltimoreDirectorSell3,312$157.21$520,679.5232,350View SEC Filing  
4/29/2016Sean E HarperEVPSell21,875$157.99$3,456,031.2542,248View SEC Filing  
8/31/2015Carbonnel Francois DeDirectorSell5,000$153.84$769,200.0015,150View SEC Filing  
8/19/2015Fred HassanDirectorBuy3,010$166.63$501,556.303,582View SEC Filing  
6/2/2015Cynthia M PattonSVPSell4,530$157.06$711,481.80View SEC Filing  
4/23/2015Stuart A TrossSVPSell3,012$169.31$509,961.72View SEC Filing  
4/22/2015Sean E HarperEVPSell28,000$171.58$4,804,240.00View SEC Filing  
3/3/2015Stuart A TrossSVPSell4,415$157.74$696,422.10View SEC Filing  
3/2/2015David BaltimoreDirectorSell3,647$158.76$578,997.72View SEC Filing  
2/11/2015Robert A BradwayCEOSell22,000$152.69$3,359,180.00View SEC Filing  
2/5/2015Frank C HerringerDirectorBuy3,000$152.29$456,870.00View SEC Filing  
12/3/2014Carbonnel Francois DeDirectorSell3,000$168.01$504,030.00View SEC Filing  
8/5/2014Cynthia M PattonSVPSell2,644$127.97$338,352.68View SEC Filing  
8/5/2014Sean E HarperEVPSell14,000$127.29$1,782,060.00View SEC Filing  
5/21/2014Thomas J.W. DittrichCAOSell4,130$112.83$465,987.9018,589View SEC Filing  
4/28/2014A Kelly MichaelCFOSell2,065$110.45$228,079.2541,041View SEC Filing  
3/6/2014Carbonnel Francois DeDirectorSell1,000$126.69$126,690.0018,343View SEC Filing  
9/4/2013Madhavan BalachandranEVPSell18,000$112.76$2,029,680.00View SEC Filing  
8/28/2013David BaltimoreDirectorSell4,582$109.66$502,462.1226,879View SEC Filing  
5/22/2013Thomas J.W. DittrichCAOSell6,130$104.78$642,301.40View SEC Filing  
5/21/2013Madhavan BalachandranEVPSell6,000$103.28$619,680.00View SEC Filing  
5/17/2013Rebecca M HendersonDirectorSell8,421$105.72$890,268.12View SEC Filing  
5/16/2013Cynthia M PattonSVPSell3,544$105.01$372,155.44View SEC Filing  
5/14/2013Judith C PelhamDirectorSell25,000$108.25$2,706,250.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Amgen (NASDAQ AMGN) News Headlines

Source:
DateHeadline
Amgens (AMGN) "Neutral" Rating Reaffirmed at UBSAmgen's (AMGN) "Neutral" Rating Reaffirmed at UBS
www.americanbankingnews.com - April 20 at 9:46 PM
Amgen (AMGN) to Report Q1 Earnings: Is a Beat in the Cards?Amgen (AMGN) to Report Q1 Earnings: Is a Beat in the Cards?
www.nasdaq.com - April 20 at 5:39 PM
Amgens (AMGN) "Market Perform" Rating Reiterated at William BlairAmgen's (AMGN) "Market Perform" Rating Reiterated at William Blair
www.americanbankingnews.com - April 20 at 4:17 PM
Amgen Announces Webcast Of 2018 First Quarter Financial ResultsAmgen Announces Webcast Of 2018 First Quarter Financial Results
finance.yahoo.com - April 19 at 5:50 PM
Amgens (AMGN) "Buy" Rating Reiterated at Jefferies GroupAmgen's (AMGN) "Buy" Rating Reiterated at Jefferies Group
www.americanbankingnews.com - April 19 at 3:36 PM
Gilead Sciences Expects Decline in Earnings in Fiscal 2018Gilead Sciences Expects Decline in Earnings in Fiscal 2018
finance.yahoo.com - April 19 at 8:27 AM
Amgen (AMGN) to Release Earnings on ThursdayAmgen (AMGN) to Release Earnings on Thursday
www.americanbankingnews.com - April 19 at 1:40 AM
Gilead Sciences May Witness Significant Drop in Revenues in 2018Gilead Sciences May Witness Significant Drop in Revenues in 2018
finance.yahoo.com - April 18 at 5:36 PM
What Analysts Recommend for Gilead Sciences in April 2018What Analysts Recommend for Gilead Sciences in April 2018
finance.yahoo.com - April 18 at 5:36 PM
Q1 2018 EPS Estimates for Amgen Lifted by Analyst (AMGN)Q1 2018 EPS Estimates for Amgen Lifted by Analyst (AMGN)
www.americanbankingnews.com - April 18 at 7:58 AM
Amgens Aimovig halved migraine days in 30 percent of trial patientsAmgen's Aimovig halved migraine days in 30 percent of trial patients
www.reuters.com - April 17 at 5:46 PM
Amgens Aimovig halved migraine days in 30 pct of trial patientsAmgen's Aimovig halved migraine days in 30 pct of trial patients
finance.yahoo.com - April 17 at 5:46 PM
Amgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig™ (erenumab) For Migraine Patients With Multiple Treatment FailuresAmgen Presents First-Of-Its-Kind Data At AAN Annual Meeting Reinforcing Robust And Consistent Efficacy Of Aimovig™ (erenumab) For Migraine Patients With Multiple Treatment Failures
finance.yahoo.com - April 17 at 5:46 PM
Amgen (AMGN) Downgraded by Zacks Investment ResearchAmgen (AMGN) Downgraded by Zacks Investment Research
www.americanbankingnews.com - April 17 at 12:47 PM
Sean E. Harper Sells 1,525 Shares of Amgen (AMGN) StockSean E. Harper Sells 1,525 Shares of Amgen (AMGN) Stock
www.americanbankingnews.com - April 16 at 7:33 PM
Analysts’ Recommendations for Johnson & Johnson on April 16Analysts’ Recommendations for Johnson & Johnson on April 16
finance.yahoo.com - April 16 at 9:02 AM
Q1 2018 EPS Estimates for Amgen (AMGN) Increased by AnalystQ1 2018 EPS Estimates for Amgen (AMGN) Increased by Analyst
www.americanbankingnews.com - April 16 at 1:44 AM
Cann Reaffirms "Buy" Rating for Amgen (AMGN)Cann Reaffirms "Buy" Rating for Amgen (AMGN)
www.americanbankingnews.com - April 15 at 11:42 PM
Amgen (AMGN) Rating Lowered to Market Perform at BMO Capital MarketsAmgen (AMGN) Rating Lowered to Market Perform at BMO Capital Markets
www.americanbankingnews.com - April 15 at 9:29 PM
Argus Boosts Amgen (AMGN) Price Target to $195.00Argus Boosts Amgen (AMGN) Price Target to $195.00
www.americanbankingnews.com - April 15 at 12:01 PM
Amgen (AMGN) Downgraded by BidaskClub to BuyAmgen (AMGN) Downgraded by BidaskClub to Buy
www.americanbankingnews.com - April 15 at 12:36 AM
BRIEF-Amgen Says CEO Robert Bradways FY 2017 Total Compensation Was $16.9 MlnBRIEF-Amgen Says CEO Robert Bradway's FY 2017 Total Compensation Was $16.9 Mln
www.reuters.com - April 13 at 5:43 PM
Amgen (AMGN) Lowered to "C+" at TheStreetAmgen (AMGN) Lowered to "C+" at TheStreet
www.americanbankingnews.com - April 13 at 10:23 AM
Short Interest in Amgen (AMGN) Drops By 51.8%Short Interest in Amgen (AMGN) Drops By 51.8%
www.americanbankingnews.com - April 13 at 2:10 AM
Form PX14A6G AMGEN INC Filed by: Mercy Investment Services, Inc.Form PX14A6G AMGEN INC Filed by: Mercy Investment Services, Inc.
www.streetinsider.com - April 12 at 5:43 PM
Exploring the Growth Trajectory of Amgen’s RepathaExploring the Growth Trajectory of Amgen’s Repatha
finance.yahoo.com - April 12 at 5:42 PM
Incyte Expected to Report Robust Revenue Growth in Fiscal 2018Incyte Expected to Report Robust Revenue Growth in Fiscal 2018
finance.yahoo.com - April 11 at 5:40 PM
Rhode Island governor says Amgen will build second plant in stateRhode Island governor says Amgen will build second plant in state
finance.yahoo.com - April 10 at 5:39 PM
Amgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing PlantAmgen Announces Rhode Island Will Be Location Of First US Next-Generation Biomanufacturing Plant
finance.yahoo.com - April 10 at 5:39 PM
Amgen Stock Performance in 1Q18Amgen Stock Performance in 1Q18
finance.yahoo.com - April 10 at 5:39 PM
Amgen picks Rhode Island for new biomanufacturing plantAmgen picks Rhode Island for new biomanufacturing plant
seekingalpha.com - April 10 at 1:43 PM
Amgen, Inc. (AMGN) Expected to Post Quarterly Sales of $5.46 BillionAmgen, Inc. (AMGN) Expected to Post Quarterly Sales of $5.46 Billion
www.americanbankingnews.com - April 10 at 2:17 AM
Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer ...Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer ...
www.prnewswire.com - April 9 at 5:39 PM
Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018Amgen To Present New Pre-Clinical Data Showcasing Robust Approach To Evaluating Potential Anti-Cancer Therapies At AACR 2018
finance.yahoo.com - April 9 at 5:39 PM
Reviewing Amgen (AMGN) and Neuralstem (CUR)Reviewing Amgen (AMGN) and Neuralstem (CUR)
www.americanbankingnews.com - April 9 at 1:36 PM
BMO Capital Markets Reiterates Hold Rating for Amgen (AMGN)BMO Capital Markets Reiterates Hold Rating for Amgen (AMGN)
www.americanbankingnews.com - April 8 at 9:42 PM
$3.21 Earnings Per Share Expected for Amgen, Inc. (AMGN) This Quarter$3.21 Earnings Per Share Expected for Amgen, Inc. (AMGN) This Quarter
www.americanbankingnews.com - April 8 at 9:14 PM
Amgen (AMGN) Downgraded to Hold at Zacks Investment ResearchAmgen (AMGN) Downgraded to Hold at Zacks Investment Research
www.americanbankingnews.com - April 7 at 9:13 AM
Amgen (AMGN) Price Target Cut to $180.00Amgen (AMGN) Price Target Cut to $180.00
www.americanbankingnews.com - April 5 at 2:40 PM
Amgen (AMGN) Upgraded to "Buy" at Zacks Investment ResearchAmgen (AMGN) Upgraded to "Buy" at Zacks Investment Research
www.americanbankingnews.com - April 5 at 2:15 PM
Amgen (AMGN) PT Lowered to $193.00 at Morgan StanleyAmgen (AMGN) PT Lowered to $193.00 at Morgan Stanley
www.americanbankingnews.com - April 4 at 7:31 PM
Amgen (AMGN) Stock Rating Reaffirmed by BMO Capital MarketsAmgen (AMGN) Stock Rating Reaffirmed by BMO Capital Markets
www.americanbankingnews.com - April 4 at 7:30 PM
Amgen (AMGN) Given a $198.00 Price Target at MizuhoAmgen (AMGN) Given a $198.00 Price Target at Mizuho
www.americanbankingnews.com - April 4 at 3:32 PM
Amgen (AMGN) Cut to Hold at Zacks Investment ResearchAmgen (AMGN) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - April 4 at 12:24 PM
Amgen (AMGN) Rating Lowered to Hold at ValuEngineAmgen (AMGN) Rating Lowered to Hold at ValuEngine
www.americanbankingnews.com - April 3 at 7:35 PM
Amgens (AMGN) Xgeva Gets EU Approval for Expanded LabelAmgen's (AMGN) Xgeva Gets EU Approval for Expanded Label
www.nasdaq.com - April 3 at 5:37 PM
European Commission Approves Expanded Indication For Amgens XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple MyelomaEuropean Commission Approves Expanded Indication For Amgen's XGEVA® (denosumab) For The Prevention Of Skeletal-Related Events In Patients With Multiple Myeloma
www.prnewswire.com - April 3 at 1:33 AM
Amgens Blincyto Gets FDA Nod for Minimum Residual DiseaseAmgen's Blincyto Gets FDA Nod for Minimum Residual Disease
www.zacks.com - April 2 at 5:43 PM
Amgen (AMGN) Stock Rating Lowered by ArgusAmgen (AMGN) Stock Rating Lowered by Argus
www.americanbankingnews.com - April 2 at 1:31 PM
Amgen (AMGN) Stock Rating Reaffirmed by Piper JaffrayAmgen (AMGN) Stock Rating Reaffirmed by Piper Jaffray
www.americanbankingnews.com - March 31 at 10:54 AM

SEC Filings

Amgen (NASDAQ:AMGN) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

Amgen (NASDAQ:AMGN) Income Statement, Balance Sheet and Cash Flow Statement

Chart

Amgen (NASDAQ AMGN) Stock Chart for Sunday, April, 22, 2018

Loading chart…

This page was last updated on 4/22/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.